PGS

New Slate of Officers and Board Members Elected at EnerGeo’s 53rd Annual Membership Meeting

Retrieved on: 
Thursday, February 22, 2024
Ex officio member, EVP, Exploration, TGS, CGG, Woodside Energy, Shearwater, SLB, PGS, Breakthrough Institute, CNCP, Energy, Fairfield Geotechnologies, Independent, Management

Houston, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Today, EnerGeo Alliance successfully concluded its 53rd Annual Membership Meeting where members elected new directors and officers.

Key Points: 
  • Houston, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Today, EnerGeo Alliance successfully concluded its 53rd Annual Membership Meeting where members elected new directors and officers.
  • Andrea Lovatini (Director, Exploration Data and Geosolutions, slb) and Irene Waage Basili (CEO, Shearwater ) have been elected directors for 2-year terms (2024-2026).
  • The virtual EnerGeo Alliance Annual Membership Meeting featured keynote speakers Dr. Vijaya Ramachandran , Director for Energy and Development at The Breakthrough Institute and Cameron Grebe , IOPER (International Offshore Petroleum Environment Regulators) Chair.
  • Industry executives Irene Waage Basili (CEO, Shearwater) and Andy Drummond (EVP, Exploration & Development, Woodside Energy ) shared their perspectives on the industry’s future.

INDECT USA Strategically Aligns With Parking Guidance Systems, Inc.

Retrieved on: 
Friday, February 9, 2024
Electronics, Reseller, Partnership, Distribution, Installation (computer programs), INDECT, PGS, Retail

VIENNA, Feb. 9, 2024 /PRNewswire/ -- INDECT Electronics & Distribution GmbH (INDECT), the world's largest provider of parking guidance system technology recently announced that its USA division has entered into a strategic partnership with Parking Guidance Systems, Inc. (PGS), the nation's largest reseller and installer of its technology.

Key Points: 
  • PGS to be the Exclusive North American Distributor, Reseller, and Installer of the INDECT Parking Guidance System.
  • VIENNA, Feb. 9, 2024 /PRNewswire/ -- INDECT Electronics & Distribution GmbH (INDECT), the world's largest provider of parking guidance system technology recently announced that its USA division has entered into a strategic partnership with Parking Guidance Systems, Inc. (PGS), the nation's largest reseller and installer of its technology.
  • However, INDECT USA will remain an operating entity and will continue to provide PGS with high level technical and equipment support."
  • This new alliance will not affect the existing supply of the INDECT system or interrupt progress of ongoing projects, according to Stephen Evans, INDECT USA General Manager.

23andMe Reports Third Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, February 7, 2024
GSK plc, PGS, Pharmacokinetics, SAN, Growth, Net, Inflammation, Table, Investigational New Drug, Research, SITC, Genetics, NK, Society, Consumer, Patient, IND, African Americans, FDA, Database, Immunotherapy, Therapy, Total, Premium, Webcast, Cancer, 23andMe, GSK, Workforce, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.
  • “The Company had a very productive third quarter, with meaningful strategic progress across all three business lines,” said Anne Wojcicki, Co-Founder & CEO of 23andMe.
  • Full year Adjusted EBITDA deficit is adjusted to be in the range of $185 to $180 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, February 7, 2024, to discuss the financial results for Q3 FY2024 and report on business progress.

TECO 2030 to Present at the Hybrid US Climate Investor Conference December 7th 2023

Retrieved on: 
Thursday, November 30, 2023
Conference, Yokogawa Electric, Partnership, OTCQX, Euronext Growth, Oslo Stock Exchange, PEM, European Green Deal, ASA, MOU, Pressure, Innovation Center station, OTC Markets Group, TECO, Hydrogen, Treasury, Memorandum of understanding, Transport, CO2, PGS, Automation, Ship, Renewable energy

TECO 2030 is building up Europe's first Giga production facility of hydrogen PEM fuel cell stacks and modules in Narvik, Norway.

Key Points: 
  • TECO 2030 is building up Europe's first Giga production facility of hydrogen PEM fuel cell stacks and modules in Narvik, Norway.
  • TECO 2030 is a Norwegian based clean tech company developing zero-emission technology for the maritime and heavy industry.
  • Each vessel will be equipped with 12 megawatts (MW) of TECO 2030 fuel cells for main propulsion onboard.
  • Aug. 02, 2023 -- TECO 2030 has signed an MoU with an undisclosed renowned European Motor Company.

23andMe Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
FDA, Research, African Americans, 23andMe, PGS, Health, Science, CORE (research service), Society for Immunotherapy of Cancer, Behavior, BRCA1, Consumer, Genetics, EBITDA, Workforce, Health Action International, Premium, Bangladesh Technical Education Board, Inflammation, BRCA2, DNA, Advertising, Pharmacokinetics, Consumer service, SITC, Science (journal), Immunotherapy, Database, Growth, Marketing, Webcast, GSK, GSK plc, Blood, Society, African, Total, Table, Pharmacogenomics, Harvard University, Lijun International Pharmaceutical (Holding) Co. Ltd., SAN, Pharmaceutical industry, Mobile phone, CD200R1, Simvastatin, Therapy

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.
  • Members of Total Health will also receive all the reports and features offered in our existing 23andMe+ Premium Membership.
  • Full year Adjusted EBITDA deficit is reaffirmed to be in the range of $180 to $160 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, November 8, 2023, to discuss the financial results for Q2 FY2024 and report on business progress.

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, FDA, Medical genetics, American College, 23andMe, DPYD, Genetic testing, ACMG, Polygene, Biomarker, Health, Ovarian cancer, Therapy, Life, BRCA1, Reading, Genetics, Citalopram, Liver, Kidney, Research, Prostate cancer, Clinical Pharmacogenetics Implementation Consortium, Pharmacogenomics, Metabolism, Genomic Health, BRCA2, Genome, Heredity, Disease, LDL, CYP2C19, Risk, Asthma, Risk assessment, Cancer, Breast cancer, Saliva, Pancreatic cancer, PGS, Fetus, Gene, SLCO1B1, Anxiety, Breast, American College of Medical Genetics and Genomics, Lijun International Pharmaceutical (Holding) Co. Ltd., Cholesterol, SAN, DNA, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.
  • Members of Total Health will also receive all the reports and features offered in the Company’s existing 23andMe+ Premium Membership .
  • As part of Total Health, members will gain access to all the premium reports and features delivered through 23andMe+ Premium.
  • The 23andMe+ Total Health membership will cost $99 per month, billed in a one-time annual payment of $1,188.

EIS Announces Acquisition of Power Grid Supply

Retrieved on: 
Thursday, November 2, 2023
Other Energy, Utilities, Oil, Gas, Manufacturing, Energy, Other Manufacturing, EIS, OEM, Growth, Original equipment manufacturer, Acquisition, PGS, Power Grid, Renewable energy

EIS, a leading specialty value-added distributor of electrical process materials and components in North America, is pleased to announce the successful acquisition of Power Grid Supply (“PGS”).

Key Points: 
  • EIS, a leading specialty value-added distributor of electrical process materials and components in North America, is pleased to announce the successful acquisition of Power Grid Supply (“PGS”).
  • The acquisition of Power Grid Supply reinforces EIS's position as a leading provider to the transformer industry.
  • "We are excited to welcome the talented team at Power Grid Supply to EIS.
  • “Power Grid Supply's technical expertise in combination with EIS’s footprint creates a national platform of industry-leading transformer solutions."

MIND Technology Announces Order Award

Retrieved on: 
Monday, October 23, 2023
Sealink, Farm, MIND Technology, Inc., Wind, PGS, Calendar, The Company, MIND, Television, Renewable energy, Marketing

THE WOODLANDS, Texas, Oct. 23, 2023 /PRNewswire/ -- MIND Technology, Inc. ("MIND" or the "Company") (Nasdaq: MIND) announced today that its Seamap unit has been awarded an order by PGS Geophysical AS ("PGS") to provide an ultra-high resolution 3-D seismic streamer system for PGS' new energy initiative.

Key Points: 
  • THE WOODLANDS, Texas, Oct. 23, 2023 /PRNewswire/ -- MIND Technology, Inc. ("MIND" or the "Company") (Nasdaq: MIND) announced today that its Seamap unit has been awarded an order by PGS Geophysical AS ("PGS") to provide an ultra-high resolution 3-D seismic streamer system for PGS' new energy initiative.
  • The value of the contract, which is expected to be delivered in calendar 2024, is in excess of $5.0 million.
  • Mark Welker, Vice President of MIND and Seamap Managing Director, stated, "We are proud to  have been selected in this competitive tender.
  • We are also pleased to continue our long-term relationship with PGS."

TECO 2030 and Pherousa Green Shipping sign supply agreement to realize ammonia powered zero-emission deep-sea shipping

Retrieved on: 
Thursday, September 14, 2023
Carbon, PGT, Internal combustion engine, Pherusa, Hydrogen, TECO, PGS, Innovation Center station, Frisbee, Fuel cell, Water, OTCQX, ISIN, OSE, Automation, Renewable energy, Coal, Ammonia

LYSAKER, Norway, Sept. 14, 2023 (GLOBE NEWSWIRE) -- TECO 2030 (OSE: TECO, OTCQX: TECFF, ISIN: NO0010887516) and Pherousa Green Shipping AS (PGS) sign green package supply agreement for up to six modern, zero-emission Ultramax dry bulk carriers of about 63.000 deadweight tons each.

Key Points: 
  • LYSAKER, Norway, Sept. 14, 2023 (GLOBE NEWSWIRE) -- TECO 2030 (OSE: TECO, OTCQX: TECFF, ISIN: NO0010887516) and Pherousa Green Shipping AS (PGS) sign green package supply agreement for up to six modern, zero-emission Ultramax dry bulk carriers of about 63.000 deadweight tons each.
  • Each vessel will be equipped with 12 megawatts (MW) of TECO 2030 fuel cells for main propulsion onboard.
  • The TECO 2030 fuel cell system will be installed in combination with a Pherousa Green Technologies AS’ (PGT) ammonia to hydrogen cracker.
  • Pherousa is an exciting company, with a clear vision of proving that hydrogen and ammonia can be utilized to fuel tomorrow’s deep-sea vessels,” said enthusiastically Tore Enger, Group CEO, TECO 2030.

23andMe Granted New FDA Clearance to Report Additional BRCA Variants

Retrieved on: 
Thursday, August 31, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., Pancreatic cancer, 23andMe, PCCP, DNA, Disease, Sanger, Ashkenazi Jews, Genetics, BRCA1, Food and Drug Administration, Cancer, Breast, Prostate, PGS, Marketing, Risk, Artificiality, Genetic testing, Entrepreneurship, BRCA2, BRCA, Health, FDA, Ovarian cancer, Gene, African Americans, Food, Saliva, Breast cancer, Prostate cancer, Birth control, Medical device, Pharmaceutical industry, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced the Company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report*. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer. 23andMe received the first FDA authorization for a direct-to-consumer genetic test for cancer risk in 2018 to report 3 variants in the BRCA1 and BRCA2 genes, primarily found in people of Ashkenazi Jewish descent. Many of the 41 BRCA variants added through this clearance are known to have a higher rate of occurrence in populations traditionally underserved by genetic testing, including the African American and Hispanic/Latino communities. This marks the Company’s fourth FDA clearance for genetic cancer risk.

Key Points: 
  • The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer.
  • In addition to the 510(k) clearance, the FDA also granted 23andMe the first-ever Predetermined Change Control Plan (PCCP), which allows the Company to add additional validated BRCA1 and BRCA2 variants and associated cancer risk information to its BRCA1/BRCA2 (Selected Variants) report without additional premarket review.
  • 23andMe also underwent robust analytical validation in order to meet FDA requirements to add variants to the BRCA1/BRCA2 (Selected Variants) report.
  • This clearance is the eighth pre-market authorization granted by the FDA to 23andMe covering its multiplexed Personal Genome Service.